RÉSUMÉ
Background: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare multisystem autoimmune disease. There is a need for interoperable national registries to enable reporting of real-world long-term outcomes and their predictors in AAV. Methods: The Irish National Rare Kidney Disease (RKD) registry was founded in 2012. To date, 842 patients with various forms of vasculitis have been recruited across eight nephrology, rheumatology and immunology centres. We focus here on patient- and disease- characteristics, treatment and outcomes of the 397 prospectively recruited patients with AAV. Results: Median age was 64 years (IQR 55-73), 57.9% were male, 58.9% had microscopic polyangiitis and 85.9% had renal impairment. Cumulative one- and five-year patient survival was 94% and 77% respectively. Median follow-up was 33.5 months (IQR 10.7-52.7). After controlling for age, baseline renal dysfunction (p = 0.04) and the burden of adverse events (p <0.001) were independent predictors of death overall. End-stage-kidney-disease (ESKD) occurred in 73 (18.4%) patients; one- and five-year renal survival was 85% and 79% respectively. Baseline severity of renal insufficiency (p = 0.02), urine soluble CD163 (usCD163) (p = 0.002) and "sclerotic" Berden histological class (p = 0.001) were key determinants of ESKD risk. Conclusions: Long-term outcomes of Irish AAV patients are comparable to other reported series. Our results emphasise the need for personalisation of immunosuppression, to limit treatment toxicity, particularly in those with advanced age and renal insufficiency. Baseline usCD163 is a potential biomarker for ESKD prediction and should be validated in a large independent cohort.
RÉSUMÉ
BACKGROUND: Up to 70% of patients with ANCA-associated vasculitis (AAV) develop GN, with 26% progressing to ESKD. Diagnostic-grade and noninvasive tools to detect active renal inflammation are needed. Urinary soluble CD163 (usCD163) is a promising biomarker of active renal vasculitis, but a diagnostic-grade assay, assessment of its utility in prospective diagnosis of renal vasculitis flares, and evaluation of its utility in proteinuric states are needed. METHODS: We assessed a diagnostic-grade usCD163 assay in (1) a real-world cohort of 405 patients with AAV and 121 healthy and 488 non-AAV disease controls; (2) a prospective multicenter study of 84 patients with potential renal vasculitis flare; (3) a longitudinal multicenter cohort of 65 patients with podocytopathy; and (4) a cohort of 29 patients with AAV (with or without proteinuria) and ten controls. RESULTS: We established a diagnostic reference range, with a cutoff of 250 ng/mmol for active renal vasculitis (area under the curve [AUC], 0.978). Using this cutoff, usCD163 was elevated in renal vasculitis flare (AUC, 0.95) but remained low in flare mimics, such as nonvasculitic AKI. usCD163's specificity declined in patients with AAV who had nephrotic-range proteinuria and in those with primary podocytopathy, with 62% of patients with nephrotic syndrome displaying a "positive" usCD163. In patients with AAV and significant proteinuria, usCD163 normalization to total urine protein rather than creatinine provided the greatest clinical utility for diagnosing active renal vasculitis. CONCLUSIONS: usCD163 is elevated in renal vasculitis flare and remains low in flare mimics. Nonspecific protein leakage in nephrotic syndrome elevates usCD163 in the absence of glomerular macrophage infiltration, resulting in false-positive results; this can be corrected with urine protein normalization.
Sujet(s)
Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/urine , Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Sujet âgé , Sujet âgé de 80 ans ou plus , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/diagnostic , Marqueurs biologiques , Diagnostic différentiel , Évolution de la maladie , Diagnostic précoce , Faux positifs , Femelle , Humains , Mâle , Adulte d'âge moyen , Syndrome néphrotique/urine , Études prospectives , Protéinurie/urine , Récepteurs de surface cellulaire , Valeurs de référence , Méthode en simple aveugleRÉSUMÉ
Neurological symptoms commonly occur in chronic kidney disease and may result from its treatments and complications. Impaired renal function also influences treatments for other neurological conditions, requiring various cautions, dose adjustments and timing considerations, particularly in the context of renal replacement therapy. In this review, we present six illustrative clinical vignettes to highlight these challenges.
Sujet(s)
Maladies du système nerveux , Insuffisance rénale chronique/complications , Humains , Maladies du système nerveux/diagnostic , Maladies du système nerveux/étiologie , Maladies du système nerveux/thérapie , Insuffisance rénale chronique/thérapie , Traitement substitutif de l'insuffisance rénale/effets indésirablesRÉSUMÉ
BACKGROUND AND OBJECTIVES: An environmental trigger has been proposed as an inciting factor in the development of anti-GBM disease. This multicenter, observational study sought to define the national incidence of anti-GBM disease during an 11-year period (2003-2014) in Ireland, investigate clustering of cases in time and space, and assess the effect of spatial variability in incidence on outcome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We ascertained cases by screening immunology laboratories for instances of positivity for anti-GBM antibody and the national renal histopathology registry for biopsy-proven cases. The population at risk was defined from national census data. We used a variable-window scan statistic to detect temporal clustering. A Bayesian spatial model was used to calculate standardized incidence ratios (SIRs) for each of the 26 counties. RESULTS: Seventy-nine cases were included. National incidence was 1.64 (95% confidence interval [95% CI], 0.82 to 3.35) per million population per year. A temporal cluster (n=10) was identified during a 3-month period; six cases were resident in four rural counties in the southeast. Spatial analysis revealed wide regional variation in SIRs and a cluster (n=7) in the northwest (SIR, 1.71; 95% CI, 1.02 to 3.06). There were 29 deaths and 57 cases of ESRD during a mean follow-up of 2.9 years. Greater distance from diagnosis site to treating center, stratified by median distance traveled, did not significantly affect patient (hazard ratio, 1.80; 95% CI, 0.87 to 3.77) or renal (hazard ratio, 0.76; 95% CI, 0.40 to 1.13) survival. CONCLUSIONS: To our knowledge, this is the first study to report national incidence rates of anti-GBM disease and formally investigate patterns of incidence. Clustering of cases in time and space supports the hypothesis of an environmental trigger for disease onset. The substantial variability in regional incidence highlights the need for comprehensive country-wide studies to improve our understanding of the etiology of anti-GBM disease.
Sujet(s)
Maladie des anticorps antimembrane basale glomérulaire/épidémiologie , Défaillance rénale chronique/épidémiologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Maladie des anticorps antimembrane basale glomérulaire/étiologie , Maladie des anticorps antimembrane basale glomérulaire/mortalité , Analyse de regroupements , Exposition environnementale/effets indésirables , Femelle , Humains , Incidence , Irlande/épidémiologie , Défaillance rénale chronique/étiologie , Mâle , Adulte d'âge moyen , Analyse spatio-temporelle , Taux de survieRÉSUMÉ
A specific biomarker that can separate active renal vasculitis from other causes of renal dysfunction is lacking, with a kidney biopsy often being required. Soluble CD163 (sCD163), shed by monocytes and macrophages, has been reported as a potential biomarker in diseases associated with excessive macrophage activation. Thus, we hypothesized that urinary sCD163 shed by crescent macrophages correlates with active glomerular inflammation. We detected sCD163 in rat urine early in the disease course of experimental vasculitis. Moreover, microdissected glomeruli from patients with small vessel vasculitis (SVV) had markedly higher levels of CD163 mRNA than did those from patients with lupus nephritis, diabetic nephropathy, or nephrotic syndrome. Both glomeruli and interstitium of patients with SVV strongly expressed CD163 protein. In 479 individuals, including patients with SVV, disease controls, and healthy controls, serum levels of sCD163 did not differ between the groups. However, in an inception cohort, including 177 patients with SVV, patients with active renal vasculitis had markedly higher urinary sCD163 levels than did patients in remission, disease controls, or healthy controls. Analyses in both internal and external validation cohorts confirmed these results. Setting a derived optimum cutoff for urinary sCD163 of 0.3 ng/mmol creatinine for detection of active renal vasculitis resulted in a sensitivity of 83%, specificity of 96%, and a positive likelihood ratio of 20.8. These data indicate that urinary sCD163 level associates very tightly with active renal vasculitis, and assessing this level may be a noninvasive method for diagnosing renal flare in the setting of a known diagnosis of SVV.
Sujet(s)
Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Maladies du rein/urine , Rein/vascularisation , Vascularite/urine , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques/urine , Femelle , Humains , Mâle , Adulte d'âge moyen , Récepteurs de surface cellulaire , Jeune adulteSujet(s)
Atteinte rénale aigüe/diagnostic , Infections à VIH/diagnostic , Hypertrophie/diagnostic , Rein/anatomopathologie , Atteinte rénale aigüe/complications , Atteinte rénale aigüe/anatomopathologie , Lymphome de Burkitt/complications , Lymphome de Burkitt/diagnostic , Lymphome de Burkitt/anatomopathologie , Diagnostic différentiel , Infections à VIH/complications , Infections à VIH/anatomopathologie , Humains , Hypertrophie/complications , Hypertrophie/anatomopathologie , Mâle , Jeune adulteRÉSUMÉ
Emerging experimental data suggest an important role for the T-cell immunoglobulin mucin 1 (Tim-1):Tim-4 pathway in autoimmune and alloimmune responses in vivo. Using a Tim-4 ectodomain human IgG Fc fusion protein we studied the role of Tim-4 in T-cell activation, signalling and differentiation responses in vitro. We demonstrate that Tim-4Fc can inhibit naive and pre-activated T-cell activation, proliferation and cytokine secretion via a Tim-1-independent pathway. Tim-4 contains immunoglobulin variable (IgV) and mucin domains; to identify which domain accounts for the inhibitory effect novel Tim-4 fusion proteins containing either the IgV or mucin domain were generated. We demonstrate that both IgV and mucin domains are required for the inhibitory effects and that they are mediated at least in part by inhibition of extracellular signal-regulated kinase pathway activity. Given the emerging interest in the role of the Tim family in T helper type 17 (Th17) cells, which play an important role in autoimmune disease and transplantation tolerance, our data show that Tim-4Fc can prevent polarization of CD4(+) T cells to the Th17 phenotype. Collectively, our results highlight an inhibitory role for Tim-4Fc in vitro, which we propose is mediated by a receptor other than Tim-1. In addition, this study provides new insights into the role of Tim-4Fc in regulating Th17 immune responses and may open a new avenue for autoimmune therapy.
Sujet(s)
Différenciation cellulaire , Région variable d'immunoglobuline/métabolisme , Protéines membranaires/immunologie , Mitogen-Activated Protein Kinases/métabolisme , Cellules Th17/cytologie , Cellules Th17/immunologie , Animaux , Lymphocytes T CD4+/immunologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Activation enzymatique/effets des médicaments et des substances chimiques , Humains , Immunoglobuline G/immunologie , Région variable d'immunoglobuline/génétique , Activation des lymphocytes , Protéines membranaires/pharmacologie , Souris , Souris de lignée BALB C , Mucines/génétique , Mucines/métabolisme , Liaison aux protéines , Structure tertiaire des protéines/génétique , Structure tertiaire des protéines/physiologie , Protéines recombinantes/pharmacologie , Facteur de transcription STAT-3/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Cellules Th17/effets des médicaments et des substances chimiquesRÉSUMÉ
Spina bifida (SB) is associated with chronic kidney disease as a result of vesicoureteric reflux. A proportion of patients progress to end-stage kidney disease (ESKD). Haemodialysis (HD) is probably the most common modality in ESKD, as intra-abdominal malformations and previous surgery can make peritoneal dialysis more challenging. The Chiari malformations also frequently occur in these patients. We report a case of recurrent syncope induced by HD in a patient with SB and the Chiari II malformation. Sparse data exist on the complications of HD in this patient population and on the approach to the management of dialysis-induced syncope in these individuals.
RÉSUMÉ
Rhabdomyolysis is a known complication of statin therapy and may be triggered by a pharmacokinetic interaction between a statin and a second medication. Fatal statin-induced rhabdomyolysis has an incidence of 0.15 deaths/million prescriptions. We describe 4 cases of severe rhabdomyolysis with the common feature of atorvastatin use and coadministration of fusidic acid. All cases involved long-term therapy with atorvastatin; fusidic acid was introduced for treatment of osteomyelitis or septic arthritis. Three cases occurred in the setting of diabetes mellitus, with 2 in patients with end-stage renal disease, suggesting increased susceptibility to atorvastatin-fusidic acid-induced rhabdomyolysis in these patient populations. Of the 4 patients in this series, 3 died. Fusidic acid is a unique bacteriostatic antimicrobial agent with principal antistaphylococcal activity. There have been isolated reports of rhabdomyolysis attributed to the interaction of statins and fusidic acid, the cause of which is unclear. Fusidic acid does not inhibit the cytochrome P450 3A4 isoenzyme responsible for atorvastatin metabolism; increased atorvastatin levels due to inhibition of the glucuronidation pathway may be responsible. Considering the low frequency of fusidic acid use, the appearance of 4 such cases within a short time and in a small population suggests the probability that development of this potentially fatal complication may be relatively high.
Sujet(s)
Arthrite infectieuse/traitement médicamenteux , Acide fusidique/administration et posologie , Acides heptanoïques/effets indésirables , Ostéomyélite/traitement médicamenteux , Pyrroles/effets indésirables , Rhabdomyolyse/induit chimiquement , Sujet âgé , Antibactériens/effets indésirables , Antibactériens/usage thérapeutique , Atorvastatine , Interactions médicamenteuses , Association de médicaments/effets indésirables , Études de suivi , Acide fusidique/usage thérapeutique , Acides heptanoïques/usage thérapeutique , Humains , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/effets indésirables , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/usage thérapeutique , Mâle , Adulte d'âge moyen , Pyrroles/usage thérapeutique , Rhabdomyolyse/diagnostic , Indice de gravité de la maladieRÉSUMÉ
Hemodialysis is associated with an increased risk of neoplasms which may result, at least in part, from exposure to ionizing radiation associated with frequent radiographic procedures. In order to estimate the average radiation exposure of those on hemodialysis, we conducted a retrospective study of 100 patients in a university-based dialysis unit followed for a median of 3.4 years. The number and type of radiological procedures were obtained from a central radiology database, and the cumulative effective radiation dose was calculated using standardized, procedure-specific radiation levels. The median annual radiation dose was 6.9 millisieverts (mSv) per patient-year. However, 14 patients had an annual cumulative effective radiation dose over 20 mSv, the upper averaged annual limit for occupational exposure. The median total cumulative effective radiation dose per patient over the study period was 21.7 mSv, in which 13 patients had a total cumulative effective radiation dose over 75 mSv, a value reported to be associated with a 7% increased risk of cancer-related mortality. Two-thirds of the total cumulative effective radiation dose was due to CT scanning. The average radiation exposure was significantly associated with the cause of end-stage renal disease, history of ischemic heart disease, transplant waitlist status, number of in-patient hospital days over follow-up, and death during the study period. These results highlight the substantial exposure to ionizing radiation in hemodialysis patients.
Sujet(s)
Défaillance rénale chronique/complications , Dose de rayonnement , Rayonnement ionisant , Adulte , Sujet âgé , Femelle , Humains , Défaillance rénale chronique/mortalité , Mâle , Adulte d'âge moyen , Radiographie/effets indésirables , Études rétrospectives , Appréciation des risques , Facteurs de risque , Tomodensitométrie/effets indésirables , Résultat thérapeutiqueRÉSUMÉ
The ability to induce durable transplantation tolerance predictably and consistently in the clinic is a highly desired but elusive goal. Progress is hampered by lack of appropriate experimental models in which to study resistance to transplantation tolerance. Here, we demonstrate that T helper 1-associated T box 21 transcription factor (Tbet) KO recipients exhibit allograft tolerance resistance specifically mediated by IL-17-producing CD8 T (T17) cells. Neutralization of IL-17 facilitates long-term cardiac allograft survival with combined T cell co-stimulation (CD28-CD80/86 and CD154-CD40) blockade in Tbet KO recipients. We have used this T17-biased Tbet KO model of allograft tolerance resistance to study the impact of targeting a T cell-co-stimulatory pathway, and demonstrate that targeting T cell Ig and mucin domain-1 (Tim-1) with anti-Tim-1 overcomes this resistance by specifically inhibiting the pathogenic IL-17-producing CD8 T17 cells. These data indicate that in the absence of Th1 immunity, CD8 T17 alloreactivity constitutes a barrier to transplantation tolerance. Targeting TIM-1 provides an approach to overcome resistance to tolerance in clinical transplantation.
Sujet(s)
Anticorps monoclonaux/immunologie , Lymphocytes T CD8+/métabolisme , Interleukine-17/immunologie , Protéines membranaires/immunologie , Tolérance à la transplantation/immunologie , Maladie aigüe , Animaux , Lymphocytes T CD4+/cytologie , Lymphocytes T CD4+/immunologie , Lymphocytes T CD4+/métabolisme , Lymphocytes T CD8+/cytologie , Lymphocytes T CD8+/immunologie , Technique d'immunofluorescence , Rejet du greffon/immunologie , Rejet du greffon/métabolisme , Transplantation cardiaque/méthodes , Récepteur cellulaire-1 du virus de l'hépatite A , Interleukine-17/métabolisme , Estimation de Kaplan-Meier , Protéines membranaires/métabolisme , Souris , Souris de lignée BALB C , Souris de lignée C57BL , Souris knockout , Protéines à domaine boîte-T/génétique , Protéines à domaine boîte-T/métabolisme , Transplantation homologueRÉSUMÉ
T-bet plays a crucial role in Th1 development. We investigated the role of T-bet in the development of allograft rejection in an established MHC class II-mismatched (bm12 into B6) model of chronic allograft vasculopathy (CAV). Intriguingly, and in contrast to IFN-gamma(-/-) mice that are protected from CAV, T-bet(-/-) recipients develop markedly accelerated allograft rejection accompanied by early severe vascular inflammation and vasculopathy, and infiltration by predominantly IL-17-producing CD4 T cells. Concurrently, T-bet(-/-) mice exhibit a T helper type 1 (Th1)-deficient environment characterized by profound IFN-gamma deficiency, a Th2 switch characterized by increased production of interleukin (IL) 4, IL-5, IL-10, and IL-13 cytokines, as well as increased production of the proinflammatory cytokines IL-6, IL-12p40, and IL-17. Neutralization of IL-17 inhibits accelerated allograft rejection and vasculopathy in T-bet(-/-) mice. Interestingly, CD4 but not CD8 T cell deficiency in T-bet(-/-) mice affords dramatic protection from vasculopathy and facilitates long-term graft acceptance. This is the first study establishing that in the absence of Th1-mediated alloimmune responses, CD4 Th17 cells mediate an aggressive proinflammatory response culminating in severe accelerated allograft rejection and vasculopathy. These results have important implications for the development of novel therapies to target this intractable problem in clinical solid organ transplantation.
Sujet(s)
Lymphocytes T CD4+/immunologie , Rejet du greffon/immunologie , Transplantation cardiaque/immunologie , Protéines à domaine boîte-T/métabolisme , Sous-populations de lymphocytes T/immunologie , Lymphocytes T auxiliaires/immunologie , Maladies vasculaires/immunologie , Animaux , Lymphocytes T CD8+/immunologie , Prolifération cellulaire , Cytokines/immunologie , Gènes MHC de classe II , Mémoire immunologique/immunologie , Interféron gamma/génétique , Interféron gamma/immunologie , Souris , Souris knockout , Phénotype , Facteur de transcription STAT-4/génétique , Facteur de transcription STAT-4/immunologie , Protéines à domaine boîte-T/génétique , Transplantation homologue/immunologieRÉSUMÉ
T cell Ig mucin 1 (TIM-1) plays an important role in regulating immune responses in autoimmune and asthma models, and it is expressed on both Th1 and Th2 cells. Using an antagonistic TIM-1-specific antibody, we studied the role of TIM-1 in alloimmunity. A short course of TIM-1-specific antibody monotherapy prolonged survival of fully MHC-mismatched vascularized mouse cardiac allografts. This prolongation was associated with inhibition of alloreactive Th1 responses and preservation of Th2 responses. TIM-1-specific antibody treatment was more effective in Th1-type cytokine-deficient Stat4(-/-) recipients as compared with Th2-type cytokine-deficient Stat6(-/-) recipients. Subtherapeutic doses of rapamycin plus TIM-1-specific antibody resulted in allograft acceptance and prevented the development of chronic allograft vasculopathy. Allograft survival via this treatment was accompanied by a Th1- to Th2-type cytokine switch. Depletion of natural Tregs abrogated the graft-protecting effect of the TIM-1-specific antibody. Importantly, CD4(+)CD25(+) Tregs obtained from long-term survivors had enhanced regulatory activity as compared with naive CD4(+)CD25(+) Tregs. Consistent with this, TIM-1-specific antibody treatment both preserved Tregs and prevented the expansion of alloreactive effector Th1 cells in an alloreactive TCR transgenic adoptive transfer model. These studies define previously unknown functions of TIM-1 in regulating alloimmune responses in vivo and may provide a novel approach to promoting transplantation tolerance.
Sujet(s)
Survie du greffon/immunologie , Protéines membranaires/physiologie , Lymphocytes T régulateurs/immunologie , Tolérance à la transplantation/immunologie , Animaux , Anticorps bloquants/pharmacologie , Anticorps monoclonaux/pharmacologie , Cytokines/métabolisme , Survie du greffon/effets des médicaments et des substances chimiques , Transplantation cardiaque/immunologie , Transplantation cardiaque/anatomopathologie , Récepteur cellulaire-1 du virus de l'hépatite A , Immunosuppresseurs/pharmacologie , Déplétion lymphocytaire , Protéines membranaires/antagonistes et inhibiteurs , Souris , Souris transgéniques , Modèles animaux , Sirolimus/pharmacologie , Lymphocytes T régulateurs/effets des médicaments et des substances chimiques , Lymphocytes auxiliaires Th1/immunologie , Lymphocytes auxiliaires Th2/immunologie , Tolérance à la transplantation/effets des médicaments et des substances chimiquesRÉSUMÉ
Delayed ICOS-B7h signal blockade promotes significant prolongation of cardiac allograft survival in wild-type but not in CD8-deficient C57BL/6 recipients of fully MHC-mismatched BALB/c heart allografts, suggesting the possible generation of CD8(+) regulatory T cells in vivo. We now show that the administration of a blocking anti-ICOS mAb results in the generation of regulatory CD8(+) T cells. These cells can transfer protection and prolong the survival of donor-specific BALB/c, but not third party C3H, heart grafts in CD8-deficient C57BL/6 recipients. This is unique to ICOS-B7h blockade, because B7 blockade by CTLA4-Ig prolongs graft survival in CD8-deficient mice and does not result in the generation of regulatory CD8(+) T cells. Those cells localize to the graft, produce both IFN-gamma and IL-4 after allostimulation in vitro, prohibit the expansion of alloreactive CD4(+) T cells, and appear to mediate a Th2 switch of recipient CD4(+) T cells after adoptive transfer in vivo. Finally, these cells are not confined to the CD28-negative population but express programmed death 1, a molecule required for their regulatory function in vivo. CD8(+)PD1(+) T cells suppress alloreactive CD4(+) T cells but do not inhibit the functions by alloreactive CD8(+) T cells in vitro. These results describe a novel allospecific regulatory CD8(+)PD1(+) T cell induced by ICOS-B7h blockade in vivo.
Sujet(s)
Protéines régulatrices de l'apoptose/immunologie , Lymphocytes T CD8+/immunologie , Isoantigènes/immunologie , Protéines/immunologie , Lymphocytes T régulateurs/immunologie , Tolérance à la transplantation/immunologie , Transfert adoptif , Animaux , Cytométrie en flux , Survie du greffon/immunologie , Transplantation cardiaque/immunologie , Ligand de la protéine inductible de costimulation du lymphocyte T , Activation des lymphocytes/immunologie , Mâle , Souris , RT-PCR , Sous-populations de lymphocytes T/immunologie , Transplantation homologue/immunologieRÉSUMÉ
T cell-depleting agents are being tested as part of clinical tolerance strategies in humans with autoimmunity and transplantation. The immunosuppressive activity of anti-thymocyte globulin (ATG) has been thought to result primarily from depletion of peripheral lymphocytes. Herein is reported for the first time that ATG but not anti-CD52 mAb (alemtuzumab) or the IL-2R antagonists causes rapid and sustained expansion of CD4+CD25+ T cells when cultured with human peripheral blood lymphocytes. These cells display enhanced expression of the regulatory markers glucocorticoid-induced TNF receptor, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and forkhead box P3 and efficiently suppress a direct alloimmune response of the original responder lymphocytes. It is interesting that the cells do not suppress memory responses to the recall antigen mumps. Ex vivo expansion of regulatory T cells is due mainly to conversion of CD4+CD25- into CD4+CD25+ T cells and to a lesser degree to proliferation of natural CD4+CD25+ T cells. The induction of regulatory T cells depends on production of Th2 cytokines in the generating cultures. These novel data suggest that ATG not only may promote expansion/generation of regulatory T cells but also may be useful in future ex vivo expansion of these cells for cellular therapy in autoimmunity and clinical transplantation.
Sujet(s)
Sérum antilymphocyte/pharmacologie , Antigènes CD4/immunologie , Cytokines/métabolisme , Facteurs de transcription Forkhead/immunologie , Immunosuppresseurs/pharmacologie , Sous-unité alpha du récepteur à l'interleukine-2/immunologie , Test ELISA , Cytométrie en flux , Humains , Lymphocytes T régulateurs/effets des médicaments et des substances chimiques , Lymphocytes T régulateurs/immunologie , Lymphocytes auxiliaires Th2/immunologie , Lymphocytes auxiliaires Th2/métabolismeRÉSUMÉ
Memory T cells can be a significant barrier to the induction of transplant tolerance. However, the molecular pathways that can regulate memory T cell-mediated rejection are poorly defined. In the present study we tested the hypothesis that the novel alternative costimulatory molecules (i.e., ICOS, 4-1BB, OX40, or CD30) may play a critical role in memory T cell activation and memory T cell-mediated rejection. We found that memory T cells, generated by either homeostatic proliferation or donor Ag priming, induced prompt skin allograft rejection regardless of CD28/CD154 blockade. Phenotypic analysis showed that, in contrast to naive T cells, such memory T cells expressed high levels of OX40, 4-1BB, and ICOS on the cell surface. In a skin transplant model in which rejection was mediated by memory T cells, blocking the OX40/OX40 ligand pathway alone did not prolong the skin allograft survival, but blocking OX40 costimulation in combination with CD28/CD154 blockade induced long-term skin allograft survival, and 40% of the recipients accepted their skin allograft for >100 days. In contrast, blocking the ICOS/ICOS ligand and the 4-1BB/4-1BBL pathways alone or combined with CD28/CD154 blockade had no effect in preventing skin allograft rejection. OX40 blockade did not affect the homeostatic proliferation of T cells in vivo, but markedly inhibited the effector functions of memory T cells. Our data demonstrate that memory T cells resisting to CD28/CD154 blockade in transplant rejection are sensitive to OX40 blockade and suggest that OX40 is a key therapeutic target in memory T cell-mediated rejection.
Sujet(s)
Rejet du greffon/immunologie , Mémoire immunologique , Récepteurs aux facteurs de nécrose tumorale/physiologie , Lymphocytes T/immunologie , Ligand de 4-1BB , Animaux , Antigènes de différenciation des lymphocytes T/métabolisme , Antigène CD28/immunologie , Ligand de CD40/immunologie , Prolifération cellulaire , Survie cellulaire/immunologie , Cellules cultivées , Épitopes/immunologie , Protéines à homéodomaine/génétique , Protéine inductible de costimulation du lymphocyte T , Isoantigènes/immunologie , Souris , Souris de lignée C57BL , Souris de lignée DBA , Souris knockout , Récepteur au OX40 , Récepteurs aux facteurs de nécrose tumorale/métabolisme , Transplantation de peau/immunologie , Facteurs de nécrose tumorale/métabolismeRÉSUMÉ
FTY720 is a high-affinity agonist at the sphingosine 1-phosphate receptor 1 that prevents lymphocyte egress from lymphoid tissue and prolongs allograft survival in several animal models of solid organ transplantation. In this study we used a recently developed adoptive transfer model of TCR transgenic T cells to track allospecific CD4+ T cell expansion and trafficking characteristics, cytokine secretion profiles, and surface phenotype in vivo in the setting of FTY720 administration. We report that FTY720 administration had no effect on alloantigen-driven T cell activation, proliferation, acquisition of effector-memory function, or T cell apoptosis. However, FTY720 caused a reversible sequestration of alloantigen-specific effector-memory T cells in regional lymphoid tissue associated with a decrease in T cell infiltration within the allograft and a subsequent prolongation in allograft survival. Furthermore, delayed administration of FTY720 in a cardiac model of chronic allograft rejection attenuated the progression of vasculopathy and tissue fibrosis consistent with the hypothesis that FTY720 interrupts the trafficking of activated effector-memory T cells. These data have important implications for targeting the sphingosine 1-phosphate receptor 1 in solid organ transplantation.
Sujet(s)
Lymphocytes T CD4+/immunologie , Rejet du greffon/prévention et contrôle , Immunosuppresseurs/pharmacologie , Propylène glycols/pharmacologie , Transfert adoptif , Animaux , Apoptose/effets des médicaments et des substances chimiques , Apoptose/immunologie , Lymphocytes T CD4+/effets des médicaments et des substances chimiques , Chimiotaxie des leucocytes/effets des médicaments et des substances chimiques , Chimiotaxie des leucocytes/immunologie , Maladie chronique , Cytokines/effets des médicaments et des substances chimiques , Cytokines/métabolisme , Modèles animaux de maladie humaine , Chlorhydrate de fingolimod , Cytométrie en flux , Transplantation cardiaque/immunologie , Immunohistochimie , Mémoire immunologique/effets des médicaments et des substances chimiques , Activation des lymphocytes/effets des médicaments et des substances chimiques , Activation des lymphocytes/immunologie , Souris , Souris transgéniques , Récepteurs aux antigènes des cellules T/génétique , Transplantation de peau/immunologie , Sphingosine/analogues et dérivés , Transplantation homologueRÉSUMÉ
A key factor driving the underlying pathyphysiology of "chronic rejection" in organ transplantation is a persistent T cell-mediated alloimmune response. Members of both the B7 family (including CD28 and CTLA4) and the tumor necrosis factor (TNF) family, in which the CD40-CD154 pathway is preeminent, play key roles in the T cell response following alloantigen presentation. "Positive" costimulatory molecules promote full T cell activation, whereas a subgroup of costimulatory molecules delivers "negative" costimulatory signals that function to downregulate alloimmune responses. Emerging experimental data point to key differences between the various positive and negative costimulatory molecules in terms of their temporal and spatial expression profiles, their effects of T and B cell subsets, and on their relative importance within the hierarchy of costimulatory signals delivered to the T cell. In this review, we address the role of costimulatory pathways in allograft rejection and tolerance. We will address in particular the potential of the novel costimulatory pathways as targets for tolerance induction in CD28-independent alloresponses, and we will review emerging data that suggests a key role for parenchymal expression of negative costimulatory molecules in the termination of pathogenic immune responses.
Sujet(s)
Rejet du greffon/immunologie , Tolérance immunitaire/immunologie , Lymphocytes T/immunologie , Immunologie en transplantation/immunologie , Animaux , Humains , Transplantation homologueRÉSUMÉ
Negative costimulatory signals mediated via cell surface molecules such as CTLA-4 and programmed death 1 (PD-1) play a critical role in down-modulating immune responses and maintaining peripheral tolerance. However, their role in alloimmune responses remains unclear. This study examined the role of these inhibitory pathways in regulating CD28-dependent and CD28-independent CD4 and CD8 alloreactive T cells in vivo. CTLA-4 blockade accelerated graft rejection in C57BL/6 wild-type recipients and in a proportion of CD4(-/-) but not CD8(-/-) recipients of BALB/c hearts. The same treatment led to prompt rejection in CD28(-/-) and a smaller proportion of CD4(-/-)CD28(-/-) mice with no effect in CD8(-/-)CD28(-/-) recipients. These results indicate that the CTLA-4:B7 pathway provides a negative signal to alloreactive CD8(+) T cells, particularly in the presence of CD28 costimulation. In contrast, PD-1 blockade led to accelerated rejection of heart allografts only in CD28(-/-) and CD8(-/-)CD28(-/-) recipients. Interestingly, PD-1 ligand (PD-L1) blockade led to accelerated rejection in wild-type mice and in all recipients lacking CD28 costimulation. This effect was accompanied by expansion of IFN-gamma-producing alloreactive T cells and enhanced generation of effector T cells in rejecting allograft recipients. Thus, the PD-1:PD-L1 pathway down-regulates alloreactive CD4 T cells, particularly in the absence of CD28 costimulation. The differential effects of PD-1 vs PD-L1 blockade support the possible existence of a new receptor other than PD-1 for negative signaling through PD-L1. Furthermore, PD-1:PD-L1 pathway can regulate alloimmune responses independent of an intact CD28/CTLA-4:B7 pathway. Harnessing physiological mechanisms that regulate alloimmunity should lead to development of novel strategies to induce durable and reproducible transplantation tolerance.
Sujet(s)
Antigènes de différenciation/physiologie , Lymphocytes T CD4+/immunologie , Lymphocytes T CD4+/métabolisme , Lymphocytes T CD8+/immunologie , Lymphocytes T CD8+/métabolisme , Régulation négative/immunologie , Transduction du signal/immunologie , Animaux , Anticorps bloquants/administration et posologie , Antigènes CD/génétique , Antigènes CD/physiologie , Antigènes de différenciation/immunologie , Antigène CD80/génétique , Antigène CD80/immunologie , Antigène CD80/physiologie , Antigène CD86 , Antigène CD274 , Antigène CD28/génétique , Antigènes CD4/génétique , Antigènes CD8/génétique , Antigène CTLA-4 , Régulation négative/génétique , Rejet du greffon/génétique , Rejet du greffon/immunologie , Transplantation cardiaque/immunologie , Glycoprotéines membranaires/antagonistes et inhibiteurs , Glycoprotéines membranaires/déficit , Glycoprotéines membranaires/génétique , Glycoprotéines membranaires/immunologie , Glycoprotéines membranaires/physiologie , Souris , Souris de lignée BALB C , Souris de lignée C57BL , Souris knockout , Souches mutantes de souris , Peptides/antagonistes et inhibiteurs , Peptides/immunologie , Ligand-2 de la protéine-1 de mort cellulaire programmée , Récepteur-1 de mort cellulaire programmée , Transduction du signal/génétiqueRÉSUMÉ
Programmed death-1 (PD-1), an inhibitory receptor up-regulated on activated T cells, has been shown to play a critical immunoregulatory role in peripheral tolerance, but its role in alloimmune responses is poorly understood. Using a novel alloreactive TCR-transgenic model system, we examined the functions of this pathway in the regulation of alloreactive CD4+ T cell responses in vivo. PD-L1, but not PD-1 or PD-L2, blockade accelerated MHC class II-mismatched skin graft (bm12 (I-Abm12) into B6 (I-Ab)) rejection in a similar manner to CTLA-4 blockade. In an adoptive transfer model system using the recently described anti-bm12 (ABM) TCR-transgenic mice directly reactive to I-Abm12, PD-1 and PD-L1 blockade enhanced T cell proliferation early in the immune response. In contrast, at a later time point preceding accelerated allograft rejection, only PD-L1 blockade enhanced T cell proliferation. In addition, PD-L1 blockade enhanced alloreactive Th1 cell differentiation. Apoptosis of alloantigen-specific T cells was inhibited significantly by PD-L1 but not PD-1 blockade, indicating that PD-1 may not be the receptor for the apoptotic effect of the PD-L1-signaling pathway. Interestingly, the effect of PD-L1 blockade was dependent on the presence of CD4+ CD25+ regulatory T cells in vivo. These data demonstrate a critical role for the PD-1 pathway, particularly PD-1/PD-L1 interactions, in the regulation of alloimmune responses in vivo.